Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Capreomycin is an aminoglycoside antibiotic used as an adjunct drug in tuberculosis. Cyclic peptide antibiotic similar to viomycin.
- Mechanism
- Curator reviewed
Little is known about capreomycin's exact mechanism of action, but it is thought to inhibit protein synthesis by binding to the 70S ribosomal unit. Capreomycin also binds to components in the bacterial cell which result in the production of abnormal proteins. These proteins are necessary for the bacteria's survival. Therefore the production of these abnormal proteins is ultimately fatal to the bacteria.
- Primary indication
- Used in the treatment of tuberculosis in combination with other drugs.Curator reviewed · 1 structured indication
- Formula / weight
- C50H88N28O15 · 1321.4123 g/mol (avg)
- First approval
- Canada, 1994 · United States, 1971
- Brand names
- Capastat
Resolves to
VCOPTHOUUNAYKQ-WBTCAYNUSA-NSMILES[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=OWhat you can answer from here — as of August 30, 2026
Which drugs share a target with Capreomycin, and which of those have an active Phase 3 trial?